Generics Leader Optimizes Complex Pricing and Rebating

"Optimize complex pricing and rebating, while minimizing errors and risk."

Today, nearly 8 in 10 prescriptions filled in the United States are for generic drugs; however the cost of a generic drug is 80 to 85 percent lower than the comparable branded product — leading to razor thin margins. As a leading generics manufacturer, this company contends with growing competition, tightening regulatory scrutiny, and increasingly complex pricing and rebating strategies with wholesalers and government entities.

Read how this generics manufacturer responded to razor thin margins and growing competition, by integrating disparate commercial, contracts, and regulatory platforms into a single integrated revenue management system that allows for enhanced financial visibility, and more accurate and efficient pricing, rebating, and accruals processes.